Drug resistance interpretation: PR HIVDB 9.5.1 (2023-11-05)

PI Major Mutations: G48V • I54V • V82A • I84V

PI Accessory Mutations: None

PR Other Mutations: L10I • G17E • N37D • L63P • C67S • A71V • I72IV • V77I • I93L

Protease Inhibitors

atazanavir/r (ATV/r) High-Level Resistance darunavir/r (DRV/r) Low-Level Resistance fosamprenavir/r (FPV/r) High-Level Resistance indinavir/r (IDV/r) High-Level Resistance lopinavir/r (LPV/r) High-Level Resistance nelfinavir (NFV) High-Level Resistance saquinavir/r (SQV/r) High-Level Resistance tipranavir/r (TPV/r) Intermediate Resistance

PR comments

Major

- G48V is a nonpolymorphic mutation selected by SQV and less often by IDV and LPV. It confers intermediate resistance to ATV but has little if any effect on LPV susceptibility.
- IS4V is a non-polymorphic PI-selected mutation that contributes reduced susceptibility to each of the PIs except DRV.
- VB2A is a non-polymorphic mutation selected primarily by IDV and LPV. It is associated with reduced susceptibility to LPV and to a lesser extent ATV. It increases DRV susceptibility.
- 184V is a nonpolymorphic substrate-cleft mutation selected by each of the PIs. 184V reduces susceptibility to LPV, ATV, and DRV.

Other

- L10(V are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- A71V/T are polymorphic, PI-selected accessory mutations that increase the replication of viruses with other PI-resistance mutations.
- There is evidence for low-level DRV resistance. If DRV is administered it should be used twice daily.

Mutation scoring: PR

Download CSV Drug resistance mutation scores of PI: ATV/r \circ DRV/r \circ FPV/r \circ IDV/r \circ LPV/r \circ NFV \circ SQV/r \circ 10 60 15 10 15 15 20 15 20 154V + V82A 10 10 10 10 10 10 15 V82A 15 30 30 30 15 0 184V 60 60 30 60 15 60 30 60 Total 130 15 95 125 95 150 160 50

Drug resistance interpretation: RT HIVDB 9.5.1 (2023-11-05)

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations: M41L • L74LV • T215Y NNRTI Mutations: V106VA • Y181YC

RT Other Mutations: P4P5 • D123E • I135T • I142T • D177E • V179I • G196E • K275Q • T286A • A288G • I293V • P294T • E297R • E298K • A299Q • E300S

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC) zidovudine (AZT) stavudine (D4T) didanosine (DDI) emtricitabine (FTC) lamivudine (3TC) tenofovir (TDF) Intermediate Resistance High-Level Resistance High-Level Resistance Susceptible Susceptible Low-Level Resistance

Non-nucleoside Reverse Transcriptase Inhibitors

	_
doravirine (DOR)	High-Level Resistance
efavirenz (EFV)	High-Level Resistance
etravirine (ETR)	Intermediate Resistance
nevirapine (NVP)	High-Level Resistance
rilpivirine (RPV)	Intermediate Resistance

RT comments

NRT

- M41L is a TAM that usually occurs with T215Y. In combination, M41L plus T215Y confer intermediate / high-level resistance to AZT and d4T and contribute to reduced ddl, ABC and TDF susceptibility.
- . L74V causes intermediate ABC resistance. L74I causes low-level ABC resistance.
- . T215Y/F are TAMs that causes intermediate/high-level resistance to AZT and potentially low-level resistance to ABC and TDF.

NNRTI

- V106A is a non-polymorphic mutation that confers high-level resistance to NVP and DOR, and intermediate resistance to EFV. It is commonly selected in vitro and in vivo by DOR.
- Y181C is a non-polymorphic mutation selected in persons receiving NVP, ETR and RPV. It confers high-level resistance to NVP, intermediate resistance to ETR and RPV, and low-level resistance to EFV. It does not significantly reduce DOR susceptibility.

Other

- V179I is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.
- This virus is predicted to have intermediate-level reduced susceptibility to RPV. The use of the combination of CAB/RPV should be considered to be contraindicated.

Mutation scoring: RT

Drug resistance mutation scores of NRTI:



Download CSV

 Rule
 ABC ⊕
 AZT ⊕
 D4T ⊕
 DDI ⊕
 FTC ⊕
 3TC ⊕
 TDF ⊕

 M41L
 5
 15
 15
 10
 0
 0
 5

 M41L + T215Y
 10
 10
 10
 10
 5
 5
 10

 L74LV
 30
 0
 0
 60
 0
 0
 0

 T215Y
 10
 60
 40
 15
 0
 0
 10

 Total
 55
 85
 65
 95
 5
 3
 25

Drug n	esistanci	e mutatio	on scores	of NINRT

-					
Rule	DOR ÷	EFV ÷	ETR ÷	NVP ≑	RPV :
V106VA	60	45	0	60	0
Y181YC	10	30	30	60	45
Total	70	75	30	120	45

HIVDB 9.5.1 (2023-11-05)